Category Archives: Corporate

US physicians’ annual economic influence: $2.3 trillion and 12.6 million jobs. Makes me view my GP, specialists in an entirely new light.

The News: Physicians support 12.6 million jobs in the US–17.1 jobs each–and contribute $2.3 trillion to the economy, according to a new report from the American Medical Association (pdf) (AMA)…. Read more »

Ablynx soars 60% on Novo’s latest hostile bid; grab a piece of this Belgian biotech because the real action’s just starting.

The News: Denmark’s Novo Nordisk A/S (Copenhagen), the world’s biggest insulin maker, went public Monday (January 8, 2018) with a €2.6-billion ($3.1 billion) bid for Belgian biotech group Ablynx NV… Read more »

French nanocap Sensorion inks deal with Aussie implant-maker Cochlear for €1.6M capital infusion, R&D collaboration. Pearl by the Mediterranean?

The News: Sensorion SA (Montpellier FRA), a tiny biotech company pioneering novel treatments for inner-ear diseases, and Cochlear Ltd. (Sydney), the global leader in implantable hearing devices, in a joint… Read more »

London-based biotech TopiVert, although invisible, intends to shake up Allergan, Shire in the huge dry-eye space.

The News: TopiVert Pharma Ltd., a clinical-stage biotechnology company developing narrow spectrum kinase inhibitors (NSKIs) for chronic inflammatory gastrointestinal (GI) and ocular diseases, has announced results from a Phase 1/2a… Read more »

Netherlands-based, emerging biotech star arGEN-X gives shareholders two doses of great news; stock skyrockets.

The News: arGEN-X SE (Breda NLD) has smoked its target of $150 million for a US stock offering, which will support its cancer and autoimmune disease antibodies through the clinical phases…. Read more »

Micro biotech Alzinova, hiding out in southwest Sweden, using proprietary peptide technology that targets key Alzheimer’s toxins.

Background: Alzinova AB (Gothenburg) is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer’s disease (AD). The company was founded in 2011… Read more »

From across the pond, 2017’s brightest European biotech stars; perhaps under US’s radar, but still ready to soar?

Many said good riddance to 2016 for biotech and pharma; things could only get better this year–and the European industry didn’t disappoint, says Labiotech.eu, the quintessential industry observer and news… Read more »

Pfizer, Merck’s Bavencio flop illustrative of shattered Pharma model. Is industry’s collapse just around the corner?

The News: Pfizer Inc. (NYC) and its German part­ner Merck KGaA (Darmstadt) have run into a brick wall in their race to ex­pand the mar­ket for their PD-L1 check­point inhibitor Baven­cio… Read more »

Weekly medical stock spotlight: Buy, wait or run? Leaders = Otonomy, Collegium & Sage; Laggards = Selecta & Tivity.

1.Otonomy Inc. (Nasdaq:OTIC) led advancing issues last week, rocketing 73% to $5.17. A Phase 3 clinical trial (AVERTS-2) assessing Otonomy’s Otividex in patients with Ménière’s disease, achieved its primary endpoint of the… Read more »

Fancy this: Pharma gifts to docs still paying off–big time.

The News: Giving someone a box of donuts may seem like a harmless gesture, but for pharmaceutical companies it could boost sales. A new study of healthcare providers in the… Read more »